ArticleBMC pregnancy and childbirth2026
Serum osteoprotegerin levels and their association with preeclampsia severity: a case-control study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreeclampsia is a hypertensive disorder of pregnancy associated with significant maternal and neonatal morbidity and mortality. Osteoprotegerin (OPG), a glycoprotein involved in vascular homeostasis, has emerged as a potential biomarker for disease severity. This study aimed to evaluate serum OPG levels in pregnant women with and without late-onset preeclampsia and to assess its correlation with disease severity and clinical outcomes.
methodsThis case–control study was conducted at Ain Shams University Maternity Hospital between August 2022 and January 2024. Ninety pregnant women with gestational age ≥ 34 weeks were enrolled and equally divided into three groups: normotensive controls (n = 30), mild late-onset preeclampsia (n = 30), and severe late-onset preeclampsia (n = 30). Clinical assessments, laboratory investigations, and serum OPG levels (measured by ELISA) were compared among groups. Correlation, multivariate regression, and receiver operating characteristic (ROC) curve analyses were performed.
resultsSerum OPG levels were significantly higher in women with late-onset preeclampsia, particularly in the severe group (p < 0.0001). Elevated OPG levels were strongly correlated with adverse perinatal outcomes, including fetal growth restriction, preterm delivery, NICU admission, and cesarean delivery. Multivariate regression analysis demonstrated that OPG levels were independently associated with preeclampsia severity and adverse perinatal outcomes. ROC analysis showed excellent diagnostic performance of OPG in identifying severe late-onset preeclampsia (AUC = 0.976), with sensitivity and specificity of 93.3%.
conclusionSerum OPG levels are significantly elevated in late-onset preeclampsia and correlate closely with disease severity and adverse maternal and fetal outcomes. OPG shows promise as a clinical biomarker for identifying severe late-onset preeclampsia, although its utility in mild disease appears limited.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.